Welcome to our dedicated page for Scholar Rock Holding news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding stock.
Scholar Rock Holding Corporation develops biologic therapies for spinal muscular atrophy and other rare, severe, and debilitating neuromuscular diseases through its myostatin biology platform. Its principal program, apitegromab, is an anti-myostatin therapy being developed for children and adults with SMA, and its pipeline also includes subcutaneous apitegromab and SRK-439.
Recurring company updates include FDA regulatory activity for apitegromab, manufacturing and fill-finish matters tied to the program, quarterly financial results, cash and financing activity such as debt and at-the-market equity programs, and Nasdaq inducement equity grants for new employees. Scholar Rock also reports investor-conference participation and pipeline commentary related to anti-myostatin biology.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards totaling 89,304 shares to nine newly hired employees on April 17, 2026 under its 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The awards comprise 38,331 inducement stock options (exercise price $49.52) and 50,973 inducement restricted stock units. Options vest 25% after one year then quarterly over three years; RSUs vest in four equal annual installments, all subject to continued service.
Scholar Rock (NASDAQ: SRRK) will report first quarter 2026 financial results on Thursday, May 7, 2026 before markets open. A live conference call and webcast with management will start at 8:00 a.m. ET, with an archived replay available on the investor website for ~90 days.
Telephone participation requires advance registration; registrants receive a confirmation email with dial‑in instructions.
Scholar Rock (NASDAQ: SRRK) resubmitted the apitegromab BLA to the FDA on March 31, 2026, including Catalent Indiana and a second U.S. fill-finish facility. The company expects FDA acceptance within 30 days and a PDUFA action date in late September 2026.
Updates were limited in scope, mainly a standard safety update; EMA MAA review is proceeding with a decision anticipated mid-2026. Apitegromab retains Fast Track, Priority Review, Orphan Drug, Rare Pediatric Disease, and EMA PRIME designations.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards covering 60,655 shares to five newly hired employees on March 13, 2026. Awards include inducement stock options for 24,506 shares at an exercise price of $44.23 and inducement restricted stock units for 36,149 shares.
Options vest 25% after one year then quarterly over three years; RSUs vest in four equal annual installments. Awards are governed by the company’s 2022 Inducement Equity Plan under Nasdaq Rule 5635(c)(4).
Scholar Rock (NASDAQ:SRRK) reported Q4 2025 net loss of $91.0M and FY 2025 net loss of $377.9M, with no revenue. The company had $367.6M in cash and marketable securities as of December 31, 2025, and secured a debt facility of up to $550M to support apitegromab commercialization.
Apitegromab BLA resubmission is planned after a successful FDA reinspection; FDA and EMA milestones and commercial launch activities are expected through 2026.
Summary not available.
Scholar Rock (NASDAQ: SRRK) will present at three investor conferences in March 2026 via fireside chats and webcasts. Management will speak at TD Cowen on March 4, 2026 (1:50 p.m. ET, Boston), Leerink on March 10, 2026 (2:30 p.m. ET, Miami) and Barclays on March 12, 2026 (8:30 a.m. ET, Miami).
A live webcast will be available on the company Investors > Events and Presentations page, and replays will remain accessible for approximately 90 days.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards covering 114,668 shares to seven new hires: 64,226 inducement options and 50,442 inducement restricted stock units. The options carry an exercise price of $47.85, equal to the closing price on February 9, 2026.
Vesting: options vest 25% after one year then quarterly over three years; RSUs vest in four equal annual installments. Awards are issued under the company’s 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4) and are subject to standard service-based vesting conditions.
Scholar Rock (NASDAQ: SRRK) will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, before markets open. Management will host a conference call and live webcast at 8:00 a.m. ET.
Access the live audio webcast via the Investors "Events and Presentations" page on the Scholar Rock website. Telephone participants must register in advance and will receive a confirmation email with dial‑in instructions. An archived replay will be available on the company website for approximately 90 days.
Scholar Rock (NASDAQ: SRRK) granted inducement equity awards to two newly hired employees covering an aggregate of 35,200 shares of common stock: inducement stock options for 20,400 shares and inducement restricted stock units for 14,800 shares.
The options have an exercise price of $43.56, equal to the closing price on January 12, 2026. Options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in 12 equal quarterly installments. RSUs vest in four equal annual installments. All vesting is conditioned on continued service and the awards are issued under the Company’s 2022 Inducement Equity Plan pursuant to Nasdaq Listing Rule 5635(c)(4).